Streamlining CDMO Partnerships & Vendor Selection to Access Expertise & Reduce Early-Stage Burden
- How to evaluate and select RNA-specialized CDMOs that align with project needs, timelines, and modality complexity
- Establishing collaborative data-sharing and tech transfer models to ensure transparency and reduce rework
- Managing quality and IP risks while leveraging partner strengths for faster IND or clinical production